See what’s clicking on FoxBusiness.com
The US Food and Drug Administration (FDA) recognized this week that there is a nationwide shortage of Adderall (Attention Deficit Hyperactivity Disorder) (ADHD), confirming previous warnings from manufacturers, pharmacists and patients.
The largest Adderall manufacturer in the US, Teva Pharmaceuticals Industries, Ltd., said last month that labor shortages from earlier in the year caused production disruptions, but the company expected any retail-level shortages to be resolved within weeks.
The FDA Confirmed This Week That There Is An Adderall Shortage In The U.S. (JB Reed/Bloomberg via Getty Images/Getty Images)
| ticker | Safety | Last | Change | Change % |
|---|---|---|---|---|
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 7.95 | -0.26 | -3.17% |
But since then, shortages have spread to other drug companies producing generic versions of the treatment as desperate patients seek alternatives, and there are signs that the situation could worsen further.
FDA ALLOWS BIVALENT COVID BOOSTERS FOR YOUNG CHILDREN
The FDA said in its press release Wednesday that Teva is “experienced continued intermittent production delays,” indicating the disruptions from earlier in the year have not yet been resolved.
The Food and Drug Administration headquarters in White Oak, Maryland. (REUTERS/Andrew Kelly/File photo/Reuters)
Last week, an FDA spokesperson told FOX News Digital that the agency was in contact with manufacturers of Adderall-like drugs and monitoring supplies but stopped reporting a shortage.
WALMART, CVS REACH $147.5 Million OPIOID Settlement With WEST VIRGINIA
Experts say several factors are contributing to the shortages, including record-high regulations for the mixed amphetamine salts following COVID-19 lockdowns, an increase in recreational use of the stimulant and limits set by the federal government banning manufacturers from on production to be carried out when inventory is low.
New York Post columnist Karol Markowicz joined ‘Kennedy’ to discuss her recent op-ed about an increase in prescription drugs being given to children during the COVID-19 pandemic.
Despite pleas from patients dependent on the medication to focus but unable to fulfill their prescriptions, federal regulators appear hesitant to allow drugmakers to ramp up production to meet demand .
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The U.S. Drug Enforcement Administration, which regulates production quotas for controlled substances, told the Wall Street Journal there is no plan to increase production limits for ADHD drugs next year. The agency expressed concern about young adults abusing the drugs.
#Adderall #deficiency #confirmed #FDA